Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant [Yahoo! Finance]
Forte Biosciences, Inc. (FBRX)
Company Research
Source: Yahoo! Finance
DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed high grade glioma Anova helped secure $11.8m CIRM funding, and will manage the Phase 1/2a study to explore safety and efficacy of DB107 DB107 study is the 7 TH brain cancer program Anova is advancing this year LONDON & CHICAGO, May 01, 2024 BUSINESS WIRE )--Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma. In December of 2021, Denovo Biopharma announced discovery of a novel genetic biomarker, Denovo Genomic Marker 7 (DGM7 TM ), by leveraging Tocagen's randomized 403-pat
Show less
Read more
Impact Snapshot
Event Time:
FBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBRX alerts
High impacting Forte Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
FBRX
News
- Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateBusiness Wire
- Forte Biosciences, Inc. (NASDAQ: FBRX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $2.75 price target on the stock.MarketBeat
- Forte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateBusiness Wire
FBRX
Analyst Actions
- 4/8/24 - Ladenburg Thalmann
FBRX
Sec Filings
- 5/13/24 - Form 10-Q
- 5/13/24 - Form 8-K
- 4/29/24 - Form 10-K/A
- FBRX's page on the SEC website